Compare General Mills, Inc. (GIS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs ResMed Inc. — how do they compare? General Mills, Inc. trades at $38.92 (market cap $19.46B), while ResMed Inc. trades at $201.31 (market cap $28.80B). The key difference: ResMed Inc. is the larger of the two by market cap, and General Mills, Inc. pays the higher dividend (6.69%). Which is the better fit depends on your goals.
| GIS | RMD | |
|---|---|---|
Market Cap | $19.46B | $28.80B |
Sector | Consumer Staples | Health |
52-Week High | $51.27 | $293.73 |
52-Week Low | $32.17 | $182.82 |
Enterprise Value | $32.95B | $27.99B |
Dividend Yield | 6.69% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $38.95, up 6.83% in the last session, with a bullish technical signal from moving averages. The stock shows mixed earnings performance, beating estimates in Q3 2025 and Q2 2026 but missing in Q4 2025. Revenue declined to $19.49B in 2025, with net income margin turning negative at -0.48% for 2026. Recent news highlights partnerships in regenerative agriculture and cost-saving initiatives targeting $3 billion by 2030 to support margins amid soft demand.
The outlook is cautious; while valuation appears attractive with a P/E of 9.23, weak sales and profit pressure pose risks. Analyst consensus is mixed with 22.22% buy ratings, but the average price target of $36.14 suggests limited upside. Key risks include competitive pressures and macroeconomic headwinds affecting consumer spending.
ResMed (RMD) trades at $201.44, up 4.37% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 27.44% net margins and consistent revenue growth from $3.6B in 2022 to $5.15B in 2025. Recent strategic moves include divesting MatrixCare for $490M to sharpen focus on core sleep and respiratory care markets.
RMD presents a compelling growth story with analyst consensus pointing to 28% upside potential to $245.88. However, technical weakness and competitive pressures in the medical device space warrant caution. The company's strong cash flow generation and dividend payments provide shareholder value, but investors should monitor execution risks from the business portfolio restructuring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
